These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 14664471)

  • 41. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
    Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
    Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
    Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).
    Haas J; Firzlaff M
    Eur J Neurol; 2005 Jun; 12(6):425-31. PubMed ID: 15885045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glatiramer acetate for multiple sclerosis.
    La Mantia L; Munari LM; Lovati R
    Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
    Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
    BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glatiramer acetate for multiple sclerosis.
    Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
    Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
    J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
    J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
    Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
    Boĭko AN; Davydovskaia MV; Demina TL; Lashch NIu; Ovcharov VV; Popova EV; Popova NF; Romashkin AV; Boĭko OV; Khachanova NV; Sharanova SN; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):86-92. PubMed ID: 22677683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.